Karyopharm Therapeutics Stock (NASDAQ:KPTI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.77

52W Range

$0.62 - $1.95

50D Avg

$0.82

200D Avg

$1.02

Market Cap

$97.12M

Avg Vol (3M)

$760.02K

Beta

0.15

Div Yield

-

KPTI Company Profile


Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

325

IPO Date

Nov 06, 2013

Website

KPTI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License$3.50M--
License and Service$24.36M$15.67M-
Royalty$1.50M$300.00K-
Product--$98.44M
License And Other--$111.38M

Fiscal year ends in Dec 23 | Currency in USD

KPTI Financial Summary


Dec 23Dec 22Dec 21
Revenue$146.03M$157.07M$209.82M
Operating Income$-129.54M$-142.20M$-98.27M
Net Income$-143.10M$-165.29M$-124.09M
EBITDA$-129.54M$-139.93M$-97.77M
Basic EPS$-1.25$-2.02$-1.65
Diluted EPS$-1.25$-2.02$-1.65

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 05, 24 | 9:22 PM
Q1 24May 08, 24 | 12:00 AM
Q4 23Feb 29, 24 | 11:26 AM

Peer Comparison


TickerCompany
NUVBNuvation Bio Inc.
PMVPPMV Pharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
GOSSGossamer Bio, Inc.
MREOMereo BioPharma Group plc
HOOKHOOKIPA Pharma Inc.
BLUEbluebird bio, Inc.
CTMXCytomX Therapeutics, Inc.
GBIOGeneration Bio Co.
REPLReplimune Group, Inc.
RLYBRallybio Corporation
KRONKronos Bio, Inc.
ASMBAssembly Biosciences, Inc.
GLUEMonte Rosa Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
MRSNMersana Therapeutics, Inc.
NLTXNeurogene Inc.
LYRALyra Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.